- Details
- Gerhardt Attard joins Charles Ryan to discuss the optimal steroid and dose to be given with abiraterone for the management of castration-resistant prostate cancer (CRPC). The two review the risks and benefits of either the standard dose of 5mg prednisone BID compared to a lower steroid dose of 5mg daily. Dr. Attard also shares his perspective on using dexamethasone, which has also shown to have an...
|
- Details
- Neal Shore and Bertrand Tombal discuss the importance of bone health agents, particularly in patients receiving castrate-resistant prostate cancer agents. Highlights of their conversation include the use of antiresorptive therapy to reduce the risk of skeletal-related events in men with bone mCRPC and decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial. Bi...
|
- Details
- Bertrand Tombal presents the recently published results from the CARD trial: "CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent". Enzalutamide in Metastatic Prostate Cancer (mCRPC) is highly heterogeneous with the coe...
|
- Details
- Arpit Rao joins Alicia Morgans to discuss new data on PARP inhibitors in prostate cancer. Dr. Rao shares his thoughts about the future of PARP, where things stand with PARP inhibitors currently, highlighting the PROfound study, TRITON2, and last year's TOPARP-B in advanced castration-resistant prostate cancer and what he thinks in terms of personalized medicine for this population. Biographies: Ar...
|
- Details
- Mary-Ellen Taplin joins Alicia Morgans to share highlights from her 2019 Advanced Prostate Cancer Consensus Conference (APCCC) presentation on first line treatment of metastatic castration-resistant prostate cancer (mCRPC) after patients have received either docetaxel or abiraterone, enzalutamide, or apalutamide and the lack of data to guide treating physicians in this treatment setting. She highl...
|
- Details
- Fernando Maluf joins Charles Ryan to discuss the data from the first Prostate Cancer Global Consensus Conference for Developing Countries. This was a tremendous achievement in which more than a hundred physicians from all over the world, particularly from developing countries in Latin America, Africa, and the Middle East participated. Physicians that participated included several specialties: urol...
|
- Details
- Alicia Morgans and Brad McGregor discuss rare genitourinary histologies and the efforts to find treatment options for populations not always included in clinical trials. Most clinical trials are developed and designed for the most common subtypes, not including atypical variant histologies often found in bladder and prostate cancers. Given the tumor agnostic approach of immunotherapy, Brad and his...
|
- Details
- Misha Beltran shares details on the Department of Defense grant, a collaboration with Scott Tagawa and Neil Bander at Weill Cornell, and now a continuing effort at the Dana-Farber Cancer Institute. This grant is providing funding to really hone in on the therapeutic side of who are the patients most likely to benefit from PSMA scanning. Focusing on better treatment options for these patients and w...
|
- Details
- Phillip Koo joins Neal Shore to discuss radium 223 for treating men with metastatic castration-resistant prostate cancer. Radium-223 has improved overall survival (OS) and reduced symptomatic skeletal events (SSE) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases (ALSYMPCA trial). The survival benefit and the safety and tolerability profile of radium-223...
|
- Details
- Bertrand Tombal discusses the ongoing PEACE III trial evaluating enzalutamide alone versus enzalutamide plus radium-223 post the ERA-223 data. The interim safety analysis was presented at ASCO and the data demonstrated that there was an increase fracture rate with the addition of radium-223 to enzalutamide prior to mandating the use of bone protecting agents. Pathological and non-pathological frac...
|
